Yustia Tuti, Edi Setiawan Tehuteru, Ayu Rosemeilia Dewi
Objective:Neuroblastoma is the most common extracranial solid tumour in children. They account for 7-10% of the childhood cancer.Nuclear medicine has a central role in the diagnosis, staging, response evaluation andtherapy planning of neuroblastoma. International guidelines currently still using I-131 MIBG scan for neuroblastoma in the PET-CT era.We review cases of I-131 MIBG scan in high risk neuroblastoma. Method:Studies were conducted to evaluatechemotherapy response and therapy planningin children with high risk neuroblastoma using I-131 MIBG scan. I-131 MIBG whole body scan (WBS) was performed 24 and 48 hours after the administration of 1-2 mCi I-131 MIBG. SPECT of the relevant region was added for one case. Result:Four cases of high risk neuroblastomapost-chemotherapy were selected. One patient with suprarenal mass and lymph node metastases had a positive I-131 MIBG. Two patients with suprarenal mass that cannot be removed by surgery had a negative I-131 MIBG WBS. One patient with livermetastasis had a negative I-131 MIBG. Conclusion:I-131 MIBG scan is useful to evaluate of chemotherapy response and to plan appropriate therapy with I-131 MIBG for high risk neuroblastoma.